Myokardia Inc. v. Lucius Pharmaceutical

In the high-stakes world of pharmaceutical innovation, a single molecule can represent years of research, millions in investment, and—most importantly—hope for patients with life-threatening diseases. When a competitor tries to ride on the coattails of that innovation by launching a generic copy, the original innovator must move fast. This case is a textbook example of how a strong patent, paired with a well-prepared legal strategy, can stop a copycat in its tracks before any real damage is done.

Myokardia Inc., a company focused on developing therapies for serious cardiovascular conditions, held Indian Patent No. 392872. This patent covered novel pyrimidinedione compounds, including the drug Mavacamten, which is used to treat hypertrophic cardiomyopathy (HCM)—a serious and often debilitating heart condition. Myokardia had invested heavily in developing this breakthrough therapy, and its patent was the cornerstone of its commercial exclusivity in India. The defendants, Lucius Pharmaceutical, allegedly entered the market with a generic version of Mavacamten, manufacturing and selling a product that Myokardia believed fell squarely within the scope of its patented claims. This unauthorized launch prompted Myokardia to rush to the Delhi High Court seeking urgent relief.

Myokardia argued that Lucius Pharmaceutical's generic product directly infringed upon the technology protected under Indian Patent No. 392872. The plaintiffs emphasized that the defendants had no license or authorization to manufacture or sell the generic version of Mavacamten, and that this infringement was causing irreparable harm to their business and to the integrity of their patent rights. On the other side, the defendants—facing an ex-parte application—had limited opportunity to present counterarguments at this preliminary stage. The core legal friction centered on whether Myokardia had established enough of a case to justify the extraordinary remedy of an immediate injunction, without waiting for a full trial on the merits.

The Delhi High Court, after conducting a prima facie assessment of the materials placed before it, ruled in favor of Myokardia. The court found that the plaintiffs had made out a sufficiently strong case at this preliminary stage to warrant extraordinary interim relief. Consequently, an ex-parte ad-interim injunction was granted, restraining Lucius Pharmaceutical from manufacturing or selling its generic version of Mavacamten until the matter could be heard further. This order effectively froze the defendants' commercial activities around the disputed product, preserving the status quo and protecting Myokardia's patent rights during the pendency of the suit.

For founders and IP professionals in the pharmaceutical and biotech space, this case underscores a critical lesson: securing an interim injunction in a patent infringement dispute is not automatic—it requires demonstrating three essential elements. First, you must establish a strong prima facie case showing that your patent is valid and clearly being infringed. Second, you must show that the balance of convenience tilts in your favor, meaning the harm to you from continued infringement outweighs the inconvenience to the defendant from being restrained. Third, and perhaps most importantly, you must demonstrate that irreparable injury would result if the court did not act immediately—monetary damages alone are not enough. The lesson here is clear: invest in building a watertight patent portfolio from day one, document your R&D meticulously, and be prepared to move swiftly with a well-drafted infringement suit the moment a copycat emerges.